Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets

Abstract

Background: The therapeutic options for neurobehavioral disorders are still limited, and in many cases, they lack a satisfactory balance between efficacy and side effects. Objective: This work aims to review current evidence regarding the potential contribution of psychedelics and hallucinogens to the discovery of new drugs for treating different psychiatric disorders. Discussion: Ayahuasca/N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and psilocybin have evidence supporting their use in depression, and psilocybin and ayahuasca have also shown good results in treatment-resistant depression. In randomized controlled trials (RCTs) conducted with anxious patients, there were symptomatic improvements with psilocybin and LSD. Psilocybin diminished Yale–Brown Obsessive Compulsive Scale (Y-BOCS) scores in a small obsessive–compulsive disorder (OCD) sample. The evidence is less robust regarding substance use disorders, but it suggests a possible role for LSD and psilocybin in alcohol use disorders and for psilocybin in tobacco addiction. In a clinical setting, these substances seem to be safe and well-tolerated. Their mechanisms of action are not fully elucidated, but there seems to be a preponderant role of 5-hydroxytryptamine (5HT) 2A agonism, as well as connectivity changes within the default mode network (DMN) and amygdala and some other molecular modifications. Conclusion: The studies underlying the conclusions have small samples and are heterogeneous in their methods. However, the results suggest that the use of psychedelics and hallucinogens could be considered in some disorders. More studies are needed to reinforce their evidence as potential new drugs.

Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature

“…In recent years, the scientific community's interest in using psychedelics in treating mental disorders has grown, and there is now talk of a 'renaissance of psychedelic medicine' [ 75 , 76 ]. Several studies are investigating the potential role of these substances in the treatment of SUD and depression [ 77 ], in particular, ayahuasca [ 78 ], psilocybin [ 79 ], ketamine and esketamine [ 80 ]. In fact, a recent review on the use of psychedelics in treating psychiatric and addictive disorders [ 81 ] showed that in SUD subjects, the intensity of the acute psychedelic experience was the main predictor of the response to the drug.…”

Entheogens: Psychedelic religion in the United States, part two

“…Several dozen academic works similarly address psilocybin mushrooms. Most of these articles address the potential therapeutic benefits of psilocybin and other psychoactive substances (Cadoch, 2021; Goldpaugh, 2021; Goldsmith, 2011; Miller, 2017; Scheidegger, 2021; Sousa et al., 2021; Vatan, 2021).…”

Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder

“…Interestingly, some of the substances under investigations are classified as schedule I drugs ( 2 ), what is meant to point to high potential for addiction and lack of approval for medical use. One of them are psychedelics, in which case the prohibition came in the 1960s and 1970s with the rise of the counterculture movement and the growing popularity of psychedelics.…”